Propanc Biopharma, Inc. PPCB
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
4/9
Piotroski F — financial health
-36.99
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$58.9M | — | — | $13.9M |
| 2024 | — | -$1.8M | — | — | -$3.8M |
| 2023 | — | -$2.7M | — | — | -$3.1M |
| 2022 | — | -$2.7M | — | — | -$3.0M |
| 2021 | — | -$2.0M | — | — | -$3.1M |
| 2020 | — | -$4.7M | — | — | -$3.6M |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -36.99 (distress)
- Working capital / assets 0.141
- Retained earnings / assets -6.399
- EBIT / assets -2.918
- Equity / liabilities 2.429
Source: SEC EDGAR filings · CIK 0001517681 · as of 2025-06-30. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.